Tesamorelin vs CJC-1295: Research Comparison | Peptide Intel Hub

Tesamorelin is a stabilised 44-amino-acid analogue of native human GHRH with a trans-3-hexenoyl modification at the N-terminus that protects against DPP-4 degradation while preserving the full 44-residue sequence.

CJC-1295 is a truncated 30-residue GHRH analogue with four amino-acid substitutions that increase resistance to enzymatic degradation. The 'with DAC' variant adds a drug-affinity-complex (maleimidopropionic acid) modification that promotes covalent albumin binding and substantially extends the half-life; the 'no DAC' variant is the unmodified short analogue.

Both compounds act as agonists at the GHRH receptor, driving pulsatile growth-hormone release through the native pituitary axis. The downstream IGF-1 response in research models follows the GH pulse.

Tesamorelin's full 44-residue sequence preserves the receptor-binding geometry of native GHRH more closely than the truncated CJC-1295 sequence; CJC-1295 with DAC trades some receptor-binding fidelity for a substantially longer pharmacokinetic profile.

Tesamorelin has an extended pharmacokinetic profile relative to native GHRH thanks to the trans-3-hexenoyl modification — daily research cadence is typical. CJC-1295 no DAC sits in a similar daily-cadence window.

CJC-1295 with DAC has a substantially longer half-life — multi-day, suitable for weekly research cadence — driven by covalent albumin binding through the DAC modification. The trade-off is a less pulsatile GH-release profile and a sustained rather than pulsatile IGF-1 signal in research models.

Tesamorelin is widely used in metabolic, lipodystrophy and body-composition research models, often in the same protocol arms as the published clinical literature. It remains the GHRH-axis reference compound for full-sequence work.

CJC-1295 no DAC is used when a short-acting, pulsatile GHRH-axis research compound is needed. CJC-1295 with DAC is used when a sustained, multi-day GHRH-axis profile is needed — typically paired with ipamorelin in growth-hormone secretagogue research panels.

Both Tesamorelin and CJC-1295 should only be sourced from suppliers that use independent third-party verification — Janoshik Analytical is the default verifier, with orthogonal independent laboratories used when batch chemistry calls for confirmation by a second method. Minimum release specification is ≥99.0% HPLC main-peak purity with matching mass-spectrometry molecular weight and water content within the published specification for the compound.

Batch COAs for both compounds should be published by the supplier so a researcher can audit the analytical detail. The /trust/how-to-read-a-coa reference walks through every field on a modern COA.

Both compounds ship lyophilised under nitrogen. Hold the unopened vial at 2–8 °C; freeze at −20 °C for long-term storage. Reconstitution with bacteriostatic water (0.9% benzyl alcohol) supports a two-month (60-day) in-use stability window under refrigeration. Light exposure should be minimised for both compounds during reconstitution and storage.

Aliquot before any freeze. The single most common cause of measurable potency loss in research peptides is repeat freeze-thaw cycling — both Tesamorelin and CJC-1295 benefit from single-thaw aliquot workflows. Vortex gently, never shake aggressively, and keep reconstituted vials away from direct light. The /research/compound-storage-guide reference covers the per-compound stability windows in detail.

Researchers choose tesamorelin when the protocol requires the full 44-residue GHRH-axis activation with a daily research cadence and when leveraging the published clinical literature is part of the project design. Researchers choose CJC-1295 no DAC when a short-acting pulsatile profile is needed, and CJC-1295 with DAC when a sustained multi-day profile (often paired with ipamorelin) is the experimental requirement.

For multi-compound comparator studies, reputable suppliers can often reserve matched-batch inventory of both Tesamorelin and CJC-1295 against a project timeline so the experimental panel is sourced under a single analytical specification window.

Tesamorelin and CJC-1295 both function as analogues within the growth hormone-releasing hormone (GHRH) axis, yet they have taken distinct developmental and regulatory paths. Tesamorelin is a synthetic analogue of human GHRH (also known as growth hormone-releasing factor) that stimulates the synthesis and release of endogenous growth hormone (PMID 21668043). In November 2010, tesamorelin (Egrifta; Theratechnologies/EMD Serono) received approval from the US Food and Drug Administration (FDA) for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy (PMID 21283099, PMID 22298602). This makes tesamorelin the first and, so far, only treatment indicated for this specific condition (PMID 21668043).

In contrast, CJC-1295 is described as a long-acting GHRH analog (PMID 16352683) and a synthetic growth hormone analogue (PMID 26771670). It is also characterized as a growth hormone-releasing hormone analogue (PMID 41880199). While it is discussed in the context of growth hormone modulation in gerontology (PMID 42021992) and as a growth hormone secretagogue that activates IGF-1 signaling (PMID 41490200), CJC-1295 has not undergone the same rigorous approval process as tesamorelin for therapeutic indications. Instead, it is often found in the

of unapproved compounds (PMID 41966639) and is marketed direct to patients (PMID 41966639). It is considered an emerging peptide supplement (PMID 42578445) and an investigational peptide that lacks long-term safety data and systematic validation (PMID 42021992). The World Anti-Doping Agency (WADA) has prohibited the administration of GHRH and its synthetic analogs, including CJC-1295 (PMID 34665524, PMID 41880199).

Tesamorelin has a well-defined clinical application, specifically for the management of HIV-associated lipodystrophy. It is approved by the FDA for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy (PMID 21283099, PMID 22298602). In two 26-week, well-designed clinical trials in patients with HIV-associated central fat accumulation, subcutaneous tesamorelin was effective in reducing visceral adipose tissue (VAT), though it did not significantly affect subcutaneous adipose tissue (PMID 21668043). This reduction in VAT was maintained in patients who continued tesamorelin therapy until week 52 in the extension phases of these trials (PMID 21668043).

Discontinuation of tesamorelin therapy, however, resulted in the reaccumulation of VAT (PMID 21668043). Beyond fat quantity, tesamorelin also improved fat quality. In people living with HIV (PWH) who experienced VAT quantity reductions on tesamorelin, VAT and subcutaneous fat (SAT) density increased independently of changes in fat quantity, suggesting tesamorelin improves both VAT and SAT quality (PMID 33756511). Tesamorelin therapy was also associated with significant improvements in other body composition measures, such as trunk fat and waist circumference, and generally improved some body image parameters like belly image distress (PMID 21668043). Furthermore, tesamorelin has shown to be the first strategy effective against Nonalcoholic fatty liver disease (NAFLD) among the population with HIV, reducing liver fat and preventing fibrosis progression over one year (PMID 32701508).

Tesamorelin's impact extends beyond direct fat reduction in HIV-associated lipodystrophy. It is a growth hormone-releasing factor analogue (PMID 21283099) that stimulates the synthesis and release of endogenous growth hormone (PMID 21668043). This action contributes to its therapeutic effects. A study on HIV-associated NAFLD demonstrated that tesamorelin increased hepatic expression of hallmark gene sets involved in oxidative phosphorylation and decreased hepatic expression of gene sets contributing to inflammation, tissue repair, and cell division (PMID 32701508). These changes in hepatic expression correlated with improved fibrosis-related gene scores among tesamorelin-treated participants (PMID 32701508).

These findings provide a mechanistic basis for the observed clinical effects of tesamorelin on the liver (PMID 32701508). The modulation of these gene pathways highlights a broader biological influence, suggesting that tesamorelin's benefits in HIV-associated lipodystrophy may involve complex cellular and metabolic adjustments that contribute to overall health improvements in this specific patient population (PMID 32701508).

CJC-1295, a long-acting GHRH analog, has shown promising effects in preclinical settings by stimulating growth hormone (GH) and insulin-like growth factor I (IGF-I) secretion (PMID 16352683, PMID 19386527). In healthy adults, a single injection of CJC-1295 resulted in dose-dependent increases in mean plasma GH concentrations by 2- to 10-fold for 6 days or more, and in mean plasma IGF-I concentrations by 1.5- to 3-fold for 9-11 days (PMID 16352683). The estimated half-life of CJC-1295 was reported as 5.8-8.1 days (PMID 16352683). After multiple doses, mean IGF-I levels remained above baseline for up to 28 days (PMID 16352683).

CJC-1295, when combined with ipamorelin, also showed significantly improved maximum tetanic tension in murine models with glucocorticoid-induced muscle loss (PMID 41476424). These findings, however, are limited to animal studies (PMID 41476424). Despite promising preclinical data, CJC-1295 is primarily found in unregulated markets. It is often promoted for muscle growth, fat metabolism, recovery, and anti-inflammatory effects (PMID 41880199) and is popular among bodybuilders and recreational gym-goers (PMID 41880199, PMID 26771670). Its use by females has been explored through internet forums, where choice to use CJC-1295 centered on weight loss, muscle enhancement, youthful skin, improved sleep, and injury healing (PMID 26771670).

The safety and regulatory standing of tesamorelin and CJC-1295 present a marked difference. Tesamorelin is an FDA-approved drug (PMID 21283099, PMID 22298602), signifying it has undergone rigorous evaluation for both safety and efficacy in its approved indication. It was generally well tolerated in clinical trials, with treatment-emergent serious adverse events occurring in less than 4% of patients during 26 weeks of therapy (PMID 21668043). Most reported adverse events were injection-site reactions or events known to be associated with growth hormone therapy, such as arthralgia, headache, and peripheral edema (PMID 21668043). While long-term clinical experience is needed to fully assess its benefits and risks, current evidence suggests it is useful for reducing visceral adiposity in patients with HIV-associated lipodystrophy (PMID 21668043).

CJC-1295, conversely, operates largely outside regulatory oversight (PMID 41966639). It is one of many unapproved peptides in a parallel

(PMID 41966639). While initial studies in healthy adults reported no serious adverse reactions and that it was safe and relatively well tolerated, particularly at certain doses (PMID 16352683), comprehensive human safety data are scarce (PMID 41966639). Concerns have been raised regarding female use, given gender variations in growth hormone pulses affecting dosage estimation, cycling, and long-term consequences (PMID 26771670). The World Anti-Doping Agency (WADA) prohibits CJC-1295 (PMID 34665524, PMID 41880199), and its use is considered high-risk with poorly defined long-term risks (PMID 41880199). The largely unregulated supply chain for such peptides exacerbates dangers due to potential mislabeling or contamination of products (PMID 41880199). Limited data support off-label uses of tesamorelin at this time (PMID 22298602), and tesamorelin has no supporting orthopaedic evidence (PMID 41476424).

In the context of orthopedics and sports medicine, the evidence supporting the use of both tesamorelin and CJC-1295 is either absent or limited to preclinical studies. Tesamorelin, despite its FDA approval for HIV-associated lipodystrophy, has no supporting orthopedic evidence (PMID 41476424). It is recognized as one of the peptides evaluated for its potential in regenerative medicine and sports performance, but its clinical utility in musculoskeletal conditions is not established (PMID 41476424).

CJC-1295, often considered a growth hormone secretagogue, is discussed in reviews pertaining to therapeutic peptides in orthopedics (PMID 41490200) and sports medicine (PMID 41966639, PMID 41476424). However, its noted benefits, such as improved maximum tetanic tension in murine models when combined with ipamorelin, are strictly limited to animal studies (PMID 41476424). The general consensus regarding unapproved peptides like CJC-1295 is that while many demonstrate favorable tissue repair and metabolic outcomes in animal models, rigorous human safety data are scarce, and there is potential for serious harm to patients (PMID 41966639). For CJC-1295 specifically, its claimed benefits for musculoskeletal recovery and performance remain unsubstantiated by current human trials (PMID 42578445).

The detection of GHRH synthetic analogs, including tesamorelin and CJC-1295, is a significant concern in anti-doping efforts. The World Anti-Doping Agency (WADA) prohibits the administration of GHRH and its synthetic analogs (PMID 34665524). Despite evidence of their use based on admissions and intelligence, these substances do not appear to have been found in anti-doping samples by WADA-accredited laboratories, potentially due to their small concentration in urine and limited knowledge about their metabolism (PMID 34665524). However, advances are being made in detection methods.

Research has investigated the in vitro metabolism and detection of larger GHRH synthetic analogs like sermorelin, tesamorelin, CJC-1295, and CJC-1295 with drug affinity complex in fortified urine (PMID 34665524). Nineteen major in vitro metabolites were identified, synthesized, and used as reference materials to develop sensitive liquid chromatography-tandem mass spectrometry methods for detection, with limits of detection generally 1 ng/ml or less (PMID 34665524). For CJC-1295, a specific immuno-polymerase chain reaction (I-PCR) assay has been developed, capable of detecting the CJC-1295-protein conjugate at concentrations down to 0.8 pg/mL (PMID 30489688). This is particularly relevant because CJC-1295 covalently links to plasma proteins, remaining active in the bloodstream longer and preventing detection by top-down mass-spectrometry-based peptide screening protocols (PMID 30489688). This assay's effectiveness for controlling illicit use was confirmed in equine blood samples after administration to thoroughbred racehorses (PMID 30489688).

• Safety and Efficacy of Approved and Unapproved Peptide Therapies for Musculoskeletal Injuries and Athletic Performance. — Sports medicine (Auckland, N.Z.) (2026). PMID 41966639
• Tesamorelin. — Nature reviews. Drug discovery (2011). PMID 21283099
• Therapeutic Peptides in Orthopaedics: Applications, Challenges, and Future Directions. — Journal of the American Academy of Orthopaedic Surgeons. Global research & reviews (2026). PMID 41490200
• Tesamorelin: a review of its use in the management of HIV-associated lipodystrophy. — Drugs (2011). PMID 21668043
• Injectable Peptide Therapy: A Primer for Orthopaedic and Sports Medicine Physicians. — The American journal of sports medicine (2026). PMID 41476424
• Tesamorelin: a growth hormone-releasing factor analogue for HIV-associated lipodystrophy. — The Annals of pharmacotherapy (2012). PMID 22298602
• Tesamorelin improves fat quality independent of changes in fat quantity. — AIDS (London, England) (2021). PMID 33756511
• Effects of tesamorelin on hepatic transcriptomic signatures in HIV-associated NAFLD. — JCI insight (2020). PMID 32701508
• Prolonged stimulation of growth hormone (GH) and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults. — The Journal of clinical endocrinology and metabolism (2006). PMID 16352683
• Peptide Supplements and Their Therapeutic Applications in Sports Medicine. — The American journal of sports medicine (2026). PMID 42578445
• Netnography of Female Use of the Synthetic Growth Hormone CJC-1295: Pulses and Potions. — Substance use & misuse (2016). PMID 26771670
• Activation of the GH/IGF-1 axis by CJC-1295, a long-acting GHRH analog, results in serum protein profile changes in normal adult subjects. — Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society (2009). PMID 19386527
• Therapeutic peptides in gerontology: mechanisms and applications for healthy aging. — Frontiers in aging (2026). PMID 42021992
• A new era of doping? Use of peptide and peptide-analog drugs in recreational and professional sport and bodybuilding: a critical review. — The Journal of sports medicine and physical fitness (2026). PMID 41880199
• Advances in the detection of growth hormone releasing hormone synthetic analogs. — Drug testing and analysis (2021). PMID 34665524
• An immuno polymerase chain reaction screen for the detection of CJC-1295 and other growth-hormone-releasing hormone analogs in equine plasma. — Drug testing and analysis (2019). PMID 30489688

Both Tesamorelin and CJC-1295 are supplied strictly for in-vitro and preclinical research use. They are not medicines, are not approved for human consumption in Spain, the United Kingdom, the European Union or the United States, and are not dispensed against a prescription. The research-use declaration ships with every package alongside the independent third-party COA.

Comparison pages on Peptide Intel Hub exist for laboratory-research reference. Nothing on this page constitutes a recommendation for human use of either compound.